Background: World-wide, cervical cancer is the second most common cancer in women. Increasing the uptake of screening, alongside increasing informed choice is of great importance in controlling this disease through prevention and early detection.
Objectives: To assess the effectiveness of interventions aimed at women, to increase the uptake, including informed uptake, of cervical cancer screening.
Search Strategy: We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), Issue 1, 2009. MEDLINE, EMBASE and LILACS databases up to March 2009. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field.
Selection Criteria: Randomised controlled trials (RCTs) of interventions to increase uptake/informed uptake of cervical cancer screening.
Data Collection And Analysis: Two review authors independently abstracted data and assessed risk of bias. Where possible the data were synthesised in a meta-analysis.
Main Results: Thirty-eight trials met our inclusion criteria. These trials assessed the effectiveness of invitational and educational interventions, counselling, risk factor assessment and procedural interventions. Heterogeneity between trials limited statistical pooling of data. Overall, however, invitations appear to be effective methods of increasing uptake. In addition, there is limited evidence to support the use of educational materials. Secondary outcomes including cost data were incompletely documented so evidence was limited. Most trials were at moderate risk of bias. Informed uptake of cervical screening was not reported in any trials.
Authors' Conclusions: There is evidence to support the use of invitation letters to increase the uptake of cervical screening. There is limited evidence to support educational interventions but it is unclear what format is most effective. The majority of the studies are from developed countries and so the relevance to developing countries is unclear.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163962 | PMC |
http://dx.doi.org/10.1002/14651858.CD002834.pub2 | DOI Listing |
BMC Cancer
January 2025
Department of Community & Family Medicine, All India Institute of Medical Sciences, 151001, Bathinda, Punjab, India.
Introduction: Existing evidence suggests a lower uptake of cervical cancer screening among Indian women. Coverage is lower in rural than urban women, but such disparities are less explored. So, the present study was conducted to explore the self-reported coverage of cervical cancer screening in urban and rural areas stratified by socio-demographic characteristics, determine the spatial patterns and identify any regional variations, ascertain the factors contributing to urban-rural disparities and those influencing the likelihood of screening among women aged 30-49 years factors residing in urban, rural, and overall Indian settings.
View Article and Find Full Text PDFJ Control Release
January 2025
Precision Medicine in Oncology (PrMiO), and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Electronic address:
The recent approval of pembrolizumab in recurrent or metastatic cervical cancer warrants further investigations into the usefulness of immunotherapies for more durable and less radical interventions. In this study, the targeting potential of anti-PD-L1-functionalized immunoliposomes was tested in a 3D in vitro cervical cancer-on-a-chip model. Immunolipsomes were synthesized and decorated externally with monovalent anti-PD-L1 Fab' fragments of commercially available atezolizumab.
View Article and Find Full Text PDFJ Natl Cancer Inst
January 2025
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Population-level estimates in timeframes for reaching cervical cancer (CC) elimination (ie, <4 cases per 100,000 women) in the United States may mask potential disparities in achieving elimination among sub-populations. We used three independent Cancer Intervention and Surveillance Modeling Network (CISNET) models to estimate differences in the time to CC elimination across seven strata of correlated screening and human papillomavirus vaccination uptake, based on national survey data. Compared to the average population, elimination was achieved ≥22 years earlier for the high-uptake strata and ≥27 years later for the most extreme low-uptake strata.
View Article and Find Full Text PDFDiagnostics (Basel)
December 2024
CReSTIC, UR 3804, Université de Reims Champagne-Ardenne, 51687 Reims, France.
: Cervical cancer is a significant global health concern, with high incidence and mortality rates, especially in less-developed regions. [F]FDG PET/CT is now indicated at various stages of management, but its analysis is essentially based on SUVmax, a measure of [F]FDG uptake. Radiomics, by extracting a multitude of parameters, promises to improve the diagnostic and prognostic performance of the examination.
View Article and Find Full Text PDFOtol Neurotol
January 2025
Department of Otolaryngology-Head and Neck Surgery.
Objective: This study aims to identify 18F-FDG-PET imaging features for improving treatment response evaluation in patients with necrotizing otitis externa (NOE), aiding in the difficult differentiation between sterile inflammation and active infection.
Study Design: Retrospective cohort study.
Setting: Tertiary hospital.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!